Duloxetine resulted in a clinically significant improvement in peripheral neuropathy (PN) induced by oxaliplatin, with a manageable toxicity profile in this retrospective study. Additionally, duloxetine also improved depression and pain score. However, a prospective study should be conducted to conclude on efficacy and caution must be taken about duloxetine and other drugs interaction.
Dr Jeffrey Chi (Northwell Health Cancer Institute, NY, USA) presented the study, which included patients with gastrointestinal cancers [colorectal (CRC), pancreatic (PC), and gastric (GC)] receiving oxaliplatin-based chemotherapy regimens from November 2016 to November 2019 .
Duloxetine is a second-generation selective serotonin and norepinephrine reuptake inhibitor (SNRI) used for the treatment of depression, anxiety, PN associated with diabetes, or ongoing pain due to medical conditions such as fibromyalgia. In this retrospective study, the researchers evaluated ...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Sorafenib extends PFS, but not OS, for HCC transcatheter arterial chemoembolisation Next Article
Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC »